ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0060762;regulation of branching involved in mammary gland duct morphogenesis;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;93.99544391330774;8.16763571524637;0.0031459429173709623;0.7408135829017477;[TGFB1, PHB2]
GO:0045727;positive regulation of translation;8.0;0.6634067003016617;0.7067033501508309;9.123968241739727;1032.6861465930526;5.104244793218563;0.03456307596927652;0.6360313160968547;[PTAFR, CCL5, LIN28A, CD28, EIF3E, EIF3D]
GO:0045947;negative regulation of translational initiation;9.0;0.7508913569872202;0.7716863036738992;9.377209824211215;1335.4538949630598;6.832634648514029;0.044696440033937586;0.7456618788553018;[BANK1, EIF3E]
GO:0007098;centrosome cycle;4.0;1.0;0.75;9.628524252492122;37.692070457630365;6.088194173566533;0.0012615196775557923;0.5613505331661754;[HEPACAM2, UXT, NUP62]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[PHB2, PYCARD, AKT1, TNFSF11, BTK, S100A8, BEX1, TNFRSF11A, NLRP3, TGFB1, JUP, CD36, ANXA3, NFAM1, KIT, TLR4, LTF, TLR2, NLRC4]
GO:0009615;response to virus;5.0;0.7436939687323844;0.6620879962271125;8.801845679307654;27.267803904038782;4.174954806800768;9.126288572378991E-4;0.503748394835965;[CHRM2, PYCARD, STMN1, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, HMGA1, AZU1, DEFA1, CXCL10, CXCL12, IFNA5, IFNA4, IFNA7, CXCL9, IFNA2, IFNA8, MMP12, ACTA2, EEF1G, IFNG, TLR8, XCL1, TLR7, UNC93B1, CXCR4, SAMHD1, CCL8, CCL5, CCL4, CCL19, CARD9, LILRB1]
GO:0006446;regulation of translational initiation;8.0;0.622025257344104;0.686012628672052;8.744321835169467;215.8173094633638;5.433268205826786;0.007223211124770292;0.6528575887187926;[BANK1, CCL5, PPP1CA, EIF3K, EIF3H, EIF3E]
GO:0060744;mammary gland branching involved in thelarche;8.0;1.0;0.875;9.628524252492122;74.22212479985593;8.16763571524637;0.002484147721475594;0.7926932703116032;[TGFB1, PHB2]
GO:1902416;positive regulation of mRNA binding;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;43.93833929642468;7.697632086000634;0.0014705766743132473;0.7167775754447168;[EIF3E, EIF3D]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, FASLG, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, UXT, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, CCNE1, TGFB1, CBX4, CAV1, NR4A2, MXD1, IFNG, FBP1, MEIS2]
GO:0045471;response to ethanol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;69.73224034292265;5.006389003214805;0.0023338753293357085;0.5462679783062231;[EEF1B2, CLDN3, CLDN7, S100A8, CCL7, CNR1, GSN]
GO:0031536;positive regulation of exit from mitosis;9.0;1.0;0.896240625180289;9.628524252492122;562.0425168150831;8.16763571524637;0.018811057232375368;0.8139338954918922;[TGFB1, PHB2]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EHMT2, SLA2, PHB2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, FLNA, NR1H2, LGR4, GMNN, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, FASLG, HHEX, RFC1, XCL1, RBBP8, E2F7, KLF8, KLF5, UXT, ZNF608, EDNRB, RUNX2, PCBP3, EGR1, BCL11A, IFNA2, PTPRK, XPO1, CD36, ARID4A, BASP1, CCNE1, TGFB1, CBX4, CAV1, HMGA1, NR4A2, MXD1, HMGB2, IFNG, FBP1, MEIS2]
GO:0071277;cellular response to calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;5.433268205826786;0.0026274528238337297;0.6009779013089371;[NLGN1, CPNE5, PHB2, KCNH1, MEF2C, TUBG1]
GO:0000184;nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;10.0;0.8933024483968273;0.861892236059334;9.57851383191746;717.2549128915896;4.989581884898423;0.0240058764469685;0.6704084614939124;[PPP2R1A, MAGOH, EIF3E]
GO:1902808;positive regulation of cell cycle G1/S phase transition;8.0;0.8933024483968273;0.8216512241984136;9.5544162803384;106.07932343249502;6.113511981550823;0.003550379490092644;0.6876452870438905;[, ANXA1, CDC6, PHB2]
GO:0047497;mitochondrion transport along microtubule;8.0;0.811012628672052;0.780506314336026;9.446202695698167;156.37963208010012;6.832634648514029;0.005233885553189209;0.7244212536750128;[UXT]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TGFB1, PHB2, POLA2, BCL6, IFNG, AKT1, RAN]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[FBL, AKT1, MEF2C, RUNX2, GPNMB, FIGNL1, ALPL, RBMX, LGR4]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[PHB2, SLC8A1, AKT1, KCND2, PTGS2]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[RUVBL1, SKP2, ADRB2, NLRP3, BARD1, FAM105A, EIF3F]
GO:0007062;sister chromatid cohesion;5.0;0.7508913569872202;0.6656866903545304;8.801845679307654;32.565640385727406;6.113511981550823;0.001089942676536732;0.6028862989048107;[ESCO2, SMC1A, PHB2, RAD51C, PPP2R1A, BUB1]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPIB, MEF2C, PADI4, ATF3, EZH2, CHAF1B, FLNA, ZNF467, ATAD2, PKN1, RUVBL1, FOXO1, CIITA, FASLG, HHEX, E2F5, E2F7, POU2AF1, CCNH, UXT, BTK, EGR1, EGR2, EGR3, HMGA1, MXD1, HMGB2, AFF3, NUP62, CREB5, EHF, PHB2, HOXA9, MYB, NFE2, ZNF367, BRD2, PAWR, PAX5, AES, GTF2H1, TLE4, NACC2, BCL6, CNOT3, MAFF, RFC1, SMARCD3, CEBPE, KLF8, KLF5, ZNF608, EBF1, BCL11B, BCL11A, ARID4A, C5AR1, NLRP3, CBX4, NR4A2, LTF, MEIS2, RBMX]
GO:0043433;negative regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.468181602416943;278.0076986152632;4.753193106834193;0.00930466748196786;0.6755074688592472;[PHB2, PYCARD, HAVCR2, XCL1, SIK1, FLNA, NLRP3, WFS1, NLRP12, CCDC22, EZH2]
GO:0000226;microtubule cytoskeleton organization;5.0;0.579397892394798;0.5799399580583193;7.662411396119289;30.307791186580253;3.8212362582156385;0.0010143744957736317;0.4856592118117268;[UXT, STMN1, FBXO5, FIGNL1, PLK2, PTK2, TUBG1, FLNA, RANBP1, GAS2L3, MAP7D1, NAV1, PSRC1, WEE1, RAN]
GO:0006414;translational elongation;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;105.15840431616243;4.981283082083729;0.0035195571560423886;0.5778633610612594;[EEF1B2, EEF1G]
GO:0006851;mitochondrial calcium ion transmembrane transport;10.0;0.8436909121759173;0.837086467948879;9.510741216835738;118.62675870594882;6.7325511899570465;0.003970330856736533;0.7595439928109722;[PHB2]
GO:0000494;box C/D snoRNA 3'-end processing;11.0;1.0;0.9324289523296623;9.628524252492122;1197.572567598482;9.083926447120524;0.04008167609218351;0.8969813732811862;[FBL]
GO:0001732;formation of cytoplasmic translation initiation complex;7.0;1.0;0.8509193652572005;9.628524252492122;66.59596265062147;9.083926447120524;0.002228906937441061;0.8154717862087246;[EIF3D]
GO:1990258;histone glutamine methylation;10.0;1.0;0.9152410118609203;9.628524252492122;606.8342748477869;9.083926447120524;0.020310197063764877;0.8797934328124444;[FBL]
GO:0071300;cellular response to retinoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;200.602279209425;5.54296712308321;0.006713977754809188;0.606587909038952;[LYN, ABCA1, PHB2, MYB, EPHA3]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[PHB2, AKT1, PROK2, MEF2C, CLDN7, SLC30A10, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, ANXA1, DUSP1, ANXA5, PTGS2, UNG, FLNA, CCL19, GABRA5, PF4, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, CXCL12, BCL6, LRRK2, FASLG, TNFRSF1B, ADAMTS20, CX3CR1, LRP1, NLRC4, CCL5, CCL2, TIE1, IL2RB, SLC46A2, LGALS3, TCL1A, EDNRB, FLT3LG, BTC, POR, EPHA3, NAIP, EGR3, BCL11B, TNFSF14, PTK2, VNN1, CD28, NRP1, CCR5, CEACAM6, KIT, GNAI2, CXCR2, PDPN, LILRB1, GRINA, PDGFRB, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF, DLL1, TEK]
GO:0006749;glutathione metabolic process;6.0;0.8436909121759173;0.7449657686781032;9.360260265897443;147.28945980206763;5.71663061713405;0.0049296456676673804;0.6154690682008903;[MGST1, EEF1G]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[PHB2, CTGF, PYCARD, TNFSF11, PDGFRB, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, HAVCR2, KIT, CHI3L1, XCL1, CCL13, GNAI2, CCL8, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CCL20, TIE1, CD4, TEK]
GO:0031167;rRNA methylation;11.0;0.811012628672052;0.8379352666656883;9.490373914011304;683.5828709307049;6.481236761676141;0.022878903505408024;0.7638797017301124;[FBL]
GO:0033147;negative regulation of intracellular estrogen receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;234.23542340630428;7.138016298065211;0.007839648823214116;0.7400384854347593;[PHB2]
GO:0070317;negative regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;83.03241800612349;6.139487467954083;0.002779020306340262;0.6648930398837374;[EHMT2, UXT, CHEK1, RBBP8, RAD51, EZH2]
GO:0033600;negative regulation of mammary gland epithelial cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;170.73536782227262;8.390779266560578;0.005714359109156348;0.7800242071602487;[BRCA2, PHB2]
